Miller took the Government to court twice during her anti-Brexit campaign and became a hate figure for many Brexiteers - ...

A MUM has shared a shocking photo of a giant lump protruding from her breast, which doctors repeatedly dismissed a benign. But after months of being told there was nothing to worry about, Tirzah ...

Breast cancer cases and its economic impact are projected to grow substantially in India, with an annual increase rate of 5.6%. The economic burden of breast cancer to increase to $13.96 billion by ...

Coleen Nolan has expressed devastation at the death of her sister Linda Nolan, who she called a “beacon of love, kindness, and strength”. Irish singer Nolan, who was part of the family group The ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Study participants with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer who disease had progressed on endocrine therapy were randomly assigned to receive trastuzumab deruxtecan (n ...